Angle PLC Success with Parsortix in Colorectal Cancer
June 05 2017 - 1:00AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
05 June 2017
For immediate release 5 June 2017
ANGLE plc ("the Company")
SUCCESS WITH PARSORTIX IN COLORECTAL CANCER
Clinically relevant results presented at ASCO 2017 cancer
conference
Demonstrates use of the Parsortix system to predict resistance
to cancer drugs
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
is pleased to announce that researchers have presented successful
results from their work using ANGLE's Parsortix system in
colorectal cancer at the American Society of Clinical Oncology
(ASCO) Annual Meeting 2017, in Chicago.
The study, undertaken by The University of Texas MD Anderson
Cancer Center, represents the first ever analysis of meEGFR
(arginine methylation of the epidermal growth factor receptor)
status across a population of circulating tumour cells (CTCs)
isolated from colorectal cancer patients being treated with EGFR
inhibitors. meEGFR is already associated with a patient's likely
response to EGFR inhibitors, a key drug class in the treatment of
colorectal cancer. The object of the study was therefore to assess
whether the presence of meEGFR biomarker, when found in CTCs, is
predictive of an adverse duration of progression-free survival
(PFS) amongst this treatment group.
The results show that in a prospective study of 47 metastatic
colorectal cancer patients, researchers were able to use the
Parsortix system to harvest circulating tumour cells (CTCs) and
were able to analyse these cells for the presence or absence of
meEGFR.
The total number of CTCs was not correlated to PFS but the
proportion of those CTCs that were positive for the meEGFR marker
was found to be predictive: patients whose CTCs harvested by
Parsortix had a higher proportion of meEGFR positive CTCs, had
significantly shorter PFS compared to those patients whose CTCs had
lower levels.
This study is a further demonstration of the effectiveness of
Parsortix in enabling liquid biopsy analysis of patients' cancer
through a simple blood test with the potential to provide
clinically relevant information to advise treatment decisions.
Dr Scott Kopetz, Associate Professor, Department of
Gastrointestinal (GI) Medical Oncology, Division of Cancer
Medicine, MD Anderson, commented:
"We have isolated CTCs from metastatic colorectal cancer
patients' blood using the Parsortix system and then identified and
assessed the CTCs for the presence of the meEGFR marker. This could
open the opportunity for a liquid biopsy biomarker for reduced
efficacy from anti-EGFR treatments."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This colorectal cancer study adds to the body of evidence
driving adoption of Parsortix in the fast growing liquid biopsy
market. The ability to assess the patient's likely response to a
particular drug as a companion diagnostic is a key element in the
drive to provide precision medicine for patients saving money and
improving treatment."
For further information:
ANGLE plc 01483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys (Nominated adviser),
Steve Cox
Russell Kerr (Sales) 020 7397 8900
WG Partners
David Wilson
Claes Spång 020 3705 9330
FTI Consulting
Simon Conway, Mo Noonan,
Stephanie Cuthbert 020 3727 1000
Kimberly Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, China, Japan
and Australia and three extensive families of patents are being
progressed worldwide. The system is based on a microfluidic device
that captures live cells based on a combination of their size and
compressibility. Parsortix has a CE Mark for Europe and FDA
authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The Parsortix
system is designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKQDPQBKDDAK
(END) Dow Jones Newswires
June 05, 2017 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024